Scarica l'app Stockscreener
46.60
6.08%
2.67
Pre-mercato:
46.44
-0.16
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA - MarketBeat
FDA will review Moderna’s new flu shot after all - Morning Brew
Moderna’s new flu vaccine to undergo review by FDA | Health Watch - CBS News
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Griffin Daily News
FDA Reverses Decision About Moderna Flu Vaccine - The Bulwark
Stock Movers: eBay, Moderna, Vita Coco - Bloomberg
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines - The Conversation
Moderna Loses 2 Defenses In Patent Fight - GuruFocus
FDA reverses course, will review Moderna’s flu vaccine application - Honolulu Star-Advertiser
Market Today: Moderna rebounds; oil and gold jump - GuruFocus
3 Once-in-a-Decade Buying Opportunities - The Motley Fool
Moderna gets a win from the FDA, but political headwinds remain a concern for vaccine makers - The Boston Globe
Moderna’s flu vaccine back in play as FDA shifts course on review - BioWorld MedTech
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine - Law360
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? - Barchart.com
FDA backtracks on public feud with Moderna and agrees to review mRNA flu vaccine after initial rejection - Fortune
Moderna stock surges as FDA reverses course, agrees to review new flu shot - Yahoo Finance
AI for investors - MLQ.ai
US FDA reverses course, will review Moderna's flu vaccine application | Business Information & News | FE - Westlaw Today
Walmart earnings in focus, Caesars stock surges, Moderna FDA review - Yahoo Finance
Why Moderna (MRNA) Stock Is Trading Up Today - TradingView
Breaking news: The FDA reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, the company announced. In a rare move last week, the agency had declined to review the vaccine. - Facebook
FDA Reverses Course and Will Now Review Moderna’s Flu Shot - The Wall Street Journal
FDA Does 180 On Moderna Flu Vaccine, But Approval Would Come With A Catch - Citeline News & Insights
FDA plans review of Moderna flu vaccine for older adults - upi.com
FDA reverses course and will review Moderna’s mRNA-based flu vaccine - The Guardian
Moderna says FDA will now consider its new mRNA flu shot after initial refusal - PBS
Why Moderna Stock Just Popped - AOL.com
FDA reverses its stance on Moderna flu vaccine review - Medical Economics
FDA reverses course and will review Moderna’s mRNA flu shot, company says - KRDO
In reversal, US FDA will review Moderna's flu vaccine application - Yahoo Finance
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars - Benzinga
NIH director to temporarily run CDC, New York Times reports - AOL.com
FDA agrees to review Moderna's mRNA flu vaccine after refusal-to-file - WPDE
Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All. - Barron's
FDA reverses course on Moderna’s flu vaccine - BioPharma Dive
Moderna says FDA will now review its new flu vaccine, reversing earlier decision - CBS News
FDA to review Moderna's new flu vaccine - breakingthenews.net
FDA reverses course, will review Moderna’s mRNA flu vaccine candidate - The Hill
Moderna (MRNA) Gains from FDA Review of Flu Vaccine Application - GuruFocus
Moderna’s investigational flu vaccine moves forward in FDA review - Proactive financial news
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal - CNBC
Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma - marketscreener.com
FDA will now review flu vaccine it had rejected - Axios
FDA Will Review Moderna's New mRNA Flu Shot - KOA 850 AM & 94.1 FM
U.S. FDA to Initiate Review of Moderna’s Investigational mRNA Flu Vax - Contract Pharma
FDA Reopens Review of Moderna’s mRNA Flu Shot | Newswise - Newswise
Moderna got the FDA to change its mind and review its flu vaccine after some concessions - MarketWatch
Moderna Stock Pops as FDA Application Moves Forward - Schaeffer's Investment Research
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision - BioSpace
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Moderna (MRNA) Loses Key Defenses in Patent Dispute with Arbutus - GuruFocus
US FDA reverses course, will review Moderna’s revised flu vaccine application By Reuters - Investing.com
FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal - Scientific American
US FDA reverses course, will review Moderna's revised flu vaccine application - Yahoo Finance
FDA Decides to Review Moderna’s Flu Shot in Surprise Reversal - Bloomberg
Moderna Stock Jumps as FDA Initiates Review of Flu Vaccine - Barron's
Berkshire reduces Apple stake, FDA to review Moderna vaccine - Yahoo Finance
Moderna dealt blows in ongoing patent dispute with Arbutus - Seeking Alpha
0.15%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):